JP2000514044A5 - - Google Patents

Download PDF

Info

Publication number
JP2000514044A5
JP2000514044A5 JP1998502557A JP50255798A JP2000514044A5 JP 2000514044 A5 JP2000514044 A5 JP 2000514044A5 JP 1998502557 A JP1998502557 A JP 1998502557A JP 50255798 A JP50255798 A JP 50255798A JP 2000514044 A5 JP2000514044 A5 JP 2000514044A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1998502557A
Other languages
English (en)
Japanese (ja)
Other versions
JP4359651B2 (ja
JP2000514044A (ja
Filing date
Publication date
Priority claimed from GBGB9613182.6A external-priority patent/GB9613182D0/en
Application filed filed Critical
Publication of JP2000514044A publication Critical patent/JP2000514044A/ja
Publication of JP2000514044A5 publication Critical patent/JP2000514044A5/ja
Application granted granted Critical
Publication of JP4359651B2 publication Critical patent/JP4359651B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP50255798A 1996-06-24 1997-06-24 マンガン化合物を用いた抗腫瘍剤の心臓毒性の減少 Expired - Lifetime JP4359651B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9613182.6 1996-06-24
GBGB9613182.6A GB9613182D0 (en) 1996-06-24 1996-06-24 Method
PCT/GB1997/001721 WO1997049390A1 (en) 1996-06-24 1997-06-24 Reduction of cardiotoxicity of an antitumor agent using manganese compound

Publications (3)

Publication Number Publication Date
JP2000514044A JP2000514044A (ja) 2000-10-24
JP2000514044A5 true JP2000514044A5 (enExample) 2005-02-10
JP4359651B2 JP4359651B2 (ja) 2009-11-04

Family

ID=10795775

Family Applications (2)

Application Number Title Priority Date Filing Date
JP50255798A Expired - Lifetime JP4359651B2 (ja) 1996-06-24 1997-06-24 マンガン化合物を用いた抗腫瘍剤の心臓毒性の減少
JP50255898A Expired - Lifetime JP4162263B2 (ja) 1996-06-24 1997-06-24 フリーラジカル―誘発状態を治療するためのキレート化剤およびその金属キレート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP50255898A Expired - Lifetime JP4162263B2 (ja) 1996-06-24 1997-06-24 フリーラジカル―誘発状態を治療するためのキレート化剤およびその金属キレート

Country Status (14)

Country Link
US (2) US6147094A (enExample)
EP (2) EP0936915B1 (enExample)
JP (2) JP4359651B2 (enExample)
CN (2) CN1228703A (enExample)
AT (2) ATE228361T1 (enExample)
AU (2) AU720621B2 (enExample)
BR (1) BR9709942A (enExample)
CA (2) CA2259150A1 (enExample)
DE (2) DE69717447T2 (enExample)
GB (1) GB9613182D0 (enExample)
IL (1) IL127733A0 (enExample)
NO (2) NO985917L (enExample)
NZ (2) NZ333315A (enExample)
WO (2) WO1997049390A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69826528T2 (de) * 1997-12-23 2006-02-23 Amersham Health As Stickstoffoxid freisetzende chelatbildner und ihre therapeutische verwendung
GB9727224D0 (en) * 1997-12-23 1998-02-25 Nycomed Imaging As Method
KR20100075503A (ko) 1999-10-01 2010-07-02 디엠아이 바이오사이언시스, 인크 금속 결합 화합물 및 그의 용도
US7632803B2 (en) 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US7592304B2 (en) 1999-10-01 2009-09-22 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
FR2823977B1 (fr) 2001-04-26 2006-12-01 Univ Rene Descartes Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif
GB0117645D0 (en) * 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
US20040038904A1 (en) * 2002-05-21 2004-02-26 Angela Ogden Method of treating multiple sclerosis
FR2863892B1 (fr) * 2003-12-18 2007-05-11 Univ Paris Descartes Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux
PT1744764E (pt) 2004-04-22 2012-08-30 Celator Pharmaceuticals Inc Formulações lipossómicas de agentes antraciclina e análogos de citidina
BRPI0615265A8 (pt) 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
KR101678865B1 (ko) 2007-12-14 2016-11-23 플레드파르마 에이비 암의 치료에 사용하기 위한 화합물들
WO2011004325A1 (en) * 2009-07-06 2011-01-13 Pledpharma Ab Pharmaceutical compositions and therapeutic methods employing a combination of a manganese complex compound and a non-manganese complex form of the compound
HRP20200793T1 (hr) 2011-05-09 2020-10-16 Mayo Foundation For Medical Education And Research Liječenje raka
AU2012364227B2 (en) 2012-01-05 2017-12-07 Egetis Therapeutics Ab Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment
CA2917407C (en) 2012-10-01 2023-03-14 Mayo Foundation For Medical Education And Research Complexes containing albumin-containing nanoparticles and antibodies to treat cancer
KR20150080616A (ko) 2012-11-02 2015-07-09 플레드파르마 에이비 암 치료 방법
CA2950926A1 (en) 2014-06-13 2015-12-17 Mayo Foundation For Medical Education And Research Albumin-bound paclitaxel nanoparticle/rituximab complexes for treatment of cd20-expressing lymphomas
JP6600651B2 (ja) 2014-06-16 2019-10-30 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 骨髄腫の治療
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體-抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
EP3399861A4 (en) 2016-01-07 2019-08-07 Mayo Foundation for Medical Education and Research METHOD FOR THE TREATMENT OF CANCER WITH INTERFERON
US11351254B2 (en) 2016-02-12 2022-06-07 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
CA3018340A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
EP3432926A4 (en) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research METHOD FOR REDUCING THE TOXICITY OF CHEMOTHERAPEUTICS
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
EP3506950A1 (en) 2016-09-01 2019-07-10 Mayo Foundation for Medical Education and Research Methods and compositions for targeting t-cell cancers
JP7525999B2 (ja) 2016-09-01 2024-07-31 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ キャリアー-pd-l1結合剤組成物及び癌を処置する為にそれを使用する方法
CN109843924A (zh) 2016-09-06 2019-06-04 梅约医学教育与研究基金会 治疗表达pd-l1的癌症的方法
RU2756892C2 (ru) 2016-09-06 2021-10-06 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч Композиции с паклитакселом, альбумином и связывающим средством и способы их применения и получения
EP3509635A1 (en) 2016-09-06 2019-07-17 Vavotar Life Sciences LLC Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES444380A1 (es) * 1976-01-16 1977-06-16 Gosalvez Mario Un procedimiento para preparar derivados metalicos antraci- clinicos.
US4842845A (en) * 1987-05-08 1989-06-27 Salutar, Inc. Radioactive metal chelates for dipyridoxyl phosphate
US5223243A (en) * 1987-05-08 1993-06-29 Salutar, Inc. Dipyridoxyl phosphate chelating compound intermediates useful as NMRI contrast agents
US4935518A (en) * 1987-05-08 1990-06-19 Salutar, Inc. Manganese(II), chelate contrast agents derived from N,N'-bis-(pyridoxal ethylene diamine-N,N')-diacetic acid and derivatives thereof
US6204259B1 (en) * 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide

Similar Documents

Publication Publication Date Title
JP2000514405A5 (enExample)
JP2000508786A5 (enExample)
JP2000508796A5 (enExample)
JP2000506047A5 (enExample)
JP2000507775A5 (enExample)
JP2000505441A5 (enExample)
JP2000511019A5 (enExample)
JP2001504398A5 (enExample)
JP2000513097A5 (enExample)
JP2000510124A5 (enExample)
JP2000510012A5 (enExample)
JP2000507688A5 (enExample)
JP2000513558A5 (enExample)
JP2000503140A5 (enExample)
JP2000503216A5 (enExample)
JP2000512203A5 (enExample)
JP2000507908A5 (enExample)
JP2000512636A5 (enExample)
JP2000505405A5 (enExample)
JP2001505684A5 (enExample)
JP2000508668A5 (enExample)
JP2000508259A5 (enExample)
JP2000512844A5 (enExample)
JP2000512818A5 (enExample)
JP2000509294A5 (enExample)